retatrutide triple agonist obesity phase 2 trial Reports by STAT News claim that a single well-connected patient received early access to Eli Lilly's experimental weight-loss drug, Retatrutide, through the FDA's compassionate use program before the drug's official approval. According Lilly's triple agonist, retatrutide, delivered
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14



























